These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 2128856)

  • 1. Determination of pharmacokinetics of replacement factor VIII.
    Mannucci PM; Morfini M
    Semin Hematol; 1990 Apr; 27(2 Suppl 2):8-10. PubMed ID: 2128856
    [No Abstract]   [Full Text] [Related]  

  • 2. Single-dose pharmacokinetics of porcine factor VIII (Hyate C).
    Hermans C; Owens D; Longo G; Morfini M; Lee CA
    Thromb Haemost; 2002 Feb; 87(2):352-3. PubMed ID: 11858504
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetics of VWF/FVIII concentrates is a very intricate matter.
    Morfini M
    Haemophilia; 2011 Nov; 17(6):846-8. PubMed ID: 22029760
    [No Abstract]   [Full Text] [Related]  

  • 4. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
    Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
    Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended half-life factor VIII for immune tolerance induction in haemophilia.
    Malec LM; Journeycake J; Ragni MV
    Haemophilia; 2016 Nov; 22(6):e552-e554. PubMed ID: 27640873
    [No Abstract]   [Full Text] [Related]  

  • 6. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A.
    Vlot AJ; Mauser-Bunschoten EP; Zarkova AG; Haan E; Kruitwagen CL; Sixma JJ; van den Berg HM
    Thromb Haemost; 2000 Jan; 83(1):65-9. PubMed ID: 10669157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients.
    Fijnvandraat K; Berntorp E; ten Cate JW; Johnsson H; Peters M; Savidge G; Tengborn L; Spira J; Stahl C
    Thromb Haemost; 1997 Feb; 77(2):298-302. PubMed ID: 9157585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heat inactivation of extended half-life factor VIII concentrates.
    Fylling KA; Tange JI; Chen D; Pruthi RK
    Haemophilia; 2019 Mar; 25(2):e130-e131. PubMed ID: 30748064
    [No Abstract]   [Full Text] [Related]  

  • 9. Factor VIII half-life and clinical phenotype of severe hemophilia A.
    van Dijk K; van der Bom JG; Lenting PJ; de Groot PG; Mauser-Bunschoten EP; Roosendaal G; Grobbee DE; van den Berg HM
    Haematologica; 2005 Apr; 90(4):494-8. PubMed ID: 15820945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A two-phase linear regression model for biologic half-life data.
    Lee ML; Poon WY; Kingdon HS
    J Lab Clin Med; 1990 Jun; 115(6):745-8. PubMed ID: 2114470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative evaluation of the pharmacokinetics of three monoclonal factor VIII concentrates.
    Morfini M; Mannucci PM; Longo G; Cinotti S; Messori A
    Thromb Res; 1991 Feb; 61(3):285-90. PubMed ID: 1902997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous infusion of factor VIII for surgery and major bleeding.
    Hay CR; Doughty HI; Savidge GF
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S15-9. PubMed ID: 8735792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor VIII half-life and intensity of treatment in hemophilic patients.
    Vicente V
    Haematologica; 2005 Apr; 90(4):437. PubMed ID: 15820932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of factor VIII pharmacokinetics in hemophilia-A subjects undergoing surgery and description of a nomogram for dosing calculations.
    Longo G; Messori A; Morfini M; Baudo F; Ciavarella N; Cinotti S; Filimberti E; Giustarini G; Molinari AC; Ferrini PR
    Am J Hematol; 1989 Mar; 30(3):140-9. PubMed ID: 2492760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of factor VIII in humans. Obtaining clinically relevant data from comparative studies.
    Björkman S; Carlsson M; Berntorp E; Stenberg P
    Clin Pharmacokinet; 1992 May; 22(5):385-95. PubMed ID: 1505144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
    Deitcher SR; Tuller J; Johnson JA
    Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unexpected pharmacokinetics of recombinant porcine factor VIII in a patient with acquired factor VIII deficiency and spontaneous epidural haematoma.
    Shatzel JJ; Azar S; Scherber R; Gay N; Deloughery TG; VanSandt A; Kruse-Jarres R; Recht M; Taylor JA
    Haemophilia; 2017 Sep; 23(5):e453-e456. PubMed ID: 28664642
    [No Abstract]   [Full Text] [Related]  

  • 18. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
    Hellstern P; Kiehl R; Miyashita C; Schwerdt H; von Blohn G; Köhler M; Büttner M; Wenzel E
    Thromb Haemost; 1986 Dec; 56(3):353-9. PubMed ID: 3105109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phospholipid binding improves plasma survival of factor VIII.
    Pisal DS; Balu-Iyer SV
    Thromb Haemost; 2010 Nov; 104(5):1073-5. PubMed ID: 20838749
    [No Abstract]   [Full Text] [Related]  

  • 20. Extending half-life in coagulation factors: where do we stand?
    Lillicrap D
    Thromb Res; 2008; 122 Suppl 4():S2-8. PubMed ID: 18929522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.